Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.
Stanford inventors have developed a mesenchymal stem cell-based gene therapy that can target the inflammatory environment and secrete immunomodulatory cytokines. The model has been demonstrated in bone marrow mesenchymal stem cells in vitro.